Analysts Weekly Ratings Updates for Chinook Therapeutics

Slightly above 67% of Chinook Therapeutics' investor base is looking to short. The analysis of current outlook of investing in Chinook Therapeutics suggests that many traders are alarmed regarding Chinook Therapeutics' prospects. Chinook Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Chinook Therapeutics' earnings reports, geopolitical events, and overall market trends.
  
Several analysts have recently updated their ratings and price targets for Chinook Therapeutics 6142023 Chinook Therapeutics was downgraded by analysts at Evercore ISI to an outperform rating. 6132023 Chinook Therapeutics was downgraded by analysts at HC Wainwright from a buy rating to a neutral rating. 6132023 Chinook Therapeutics was downgraded

Read at thelincolnianonline.com
news
  

Chinook Therapeutics Fundamental Analysis

We analyze Chinook Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Chinook Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Chinook Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Shares Owned By Insiders

Shares Owned By Insiders Comparative Analysis

Chinook Therapeutics is currently under evaluation in shares owned by insiders category among its peers. Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.

Chinook Therapeutics Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Chinook Therapeutics stock to make a market-neutral strategy. Peer analysis of Chinook Therapeutics could also be used in its relative valuation, which is a method of valuing Chinook Therapeutics by comparing valuation metrics with similar companies.

Peers

Chinook Therapeutics Related Equities

VRDNViridian Therapeutics   2.16   
0%
13.0%
TVTXTravere Therapeutics   1.40   
0%
8.0%
RVMDRevolution Medicines   0.59   
0%
3.0%
ACLXArcellx   0.27   
0%
1.0%
SWTXSpringWorks Therapeutics   0.09   
0%
1.0%
RNAAvidity Biosciences   0.34   
2.0%
0%
PCVXVaxcyte   0.82   
5.0%
0%
ASNDAscendis Pharma   1.14   
7.0%
0%
NUVLNuvalent   2.16   
13.0%
0%
GPCRStructure Therapeutics   3.45   
21.0%
0%
KALVKalvista Pharmaceuticals   6.49   
40.0%
0%
CRNXCrinetics Pharmaceuticals   6.72   
42.0%
0%
DAWNDay One   9.87   
61.0%
0%
PLRXPliant Therapeutics   10.06   
63.0%
0%
VTYXVentyx Biosciences   12.32   
77.0%
0%
KURAKura Oncology   15.92   
100.0%
0%
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.

Other Consideration for investing in Chinook Stock

If you are still planning to invest in Chinook Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Chinook Therapeutics' history and understand the potential risks before investing.
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals